Summary
- Main use
- Treatment of acid-related gastric disorders, Helicobacter pylori eradication, and treatment and prevention of gastrointestinal disorders, ulcers, and rebleeding
- Who uses it
- Adults · Children
- Adult dosage
- 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration. 4. Renal impairment : No dose adjustment is necessary. Since there is limited experience administering this drug to patients with severe renal impairment, it should be administered with caution. 5. Hepatic impairment : No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. 6. Elderly patients : No dose adjustment is necessary.
- Children's dosage
- Adolescents 12 years of age and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. Pediatric patients under 12 years of age : There is no experience with administration of this drug to pediatric patients under 12 years of age.
Ingredients
- Manufacturer
- Kyeongdong Pharmaceutical Co., Ltd.
Efficacy & effects
Treatment of acid-related gastric disorders, Helicobacter pylori eradication, and treatment and prevention of gastrointestinal disorders, ulcers, and rebleeding
- Gastroesophageal reflux disease
- erosive reflux esophagitis
- esophagitis
- benign duodenal ulcers caused by Helicobacter pylori
- peptic ulcers
- upper gastrointestinal pain
- upper gastrointestinal discomfort
- upper gastrointestinal burning sensation
- gastric ulcers
- duodenal ulcers
- Zollinger-Ellison syndrome
- rebleeding from gastric ulcers
View approved original textHide original text
This medication is used for the treatment of gastroesophageal reflux disease, especially erosive reflux esophagitis, and for long-term maintenance therapy to prevent recurrence in esophagitis patients. It is also used in combination with antibiotics for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori. It is effective in treating upper gastrointestinal symptoms and gastric ulcers caused by nonsteroidal anti-inflammatory drugs and in preventing gastric and duodenal ulcers. The drug is also utilized in the treatment of Zollinger-Ellison syndrome and for maintenance therapy after intravenous treatment of bleeding gastric or duodenal ulcers. As such, it is used for the treatment and prevention of various gastrointestinal diseases.
Dosage and Administration
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg daily should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration. 4. Renal impairment : No dose adjustment is necessary. Since there is limited experience administering this drug to patients with severe renal impairment, it should be administered with caution. 5. Hepatic impairment : No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. 6. Elderly patients : No dose adjustment is necessary.
Children's dosage
Adolescents 12 years of age and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. Pediatric patients under 12 years of age : There is no experience with administration of this drug to pediatric patients under 12 years of age.
Precautions
This drug should not be used by individuals with specific allergic reactions or hypersensitivity to any components of this drug. Additionally, avoid concomitant use with certain antibiotics or antivirals as this may lead to side effects or interactions. It is advisable for breastfeeding women to refrain from taking this medication. Rarely, various side effects such as blood disorders, allergic reactions, neurological disorders, gastrointestinal issues, liver function abnormalities, and skin rashes may occur when taking this medication. Regular health check-ups are required for long-term use, especially when taken for more than one year, to closely monitor overall health status, such as magnesium levels. This medication reduces gastric acid secretion, which may promote bacterial growth in the gastrointestinal tract, potentially increasing the risk of diarrhea or infections. The risk of fractures may be increased, so individuals with osteoporosis or at risk should consult their doctor. Individuals with specific genetic metabolic disorders may experience issues due to the drug's components, so prior verification is necessary before use. Given that this drug interacts with many other medications, anyone currently taking medication should inform their healthcare provider, particularly when taking anticoagulants, anticonvulsants, and antidepressants. Due to limited safety data during pregnancy, it is recommended to consult a physician before use. In case of overdose, there is no specific antidote; appropriate treatment should be administered based on symptoms, and it should be kept out of reach of children.
Side effects
Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal soreness, facial edema, facial flushing, fatigue, flu-like symptoms, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorder, tongue swelling, ulcerative stomatitis, ear pain, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, decreased appetite, apathy, increased appetite, confusion, worsening depression, hypertonicity, sensory loss, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorder, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, olfactory disturbance, loss of taste, taste perversion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcers, esophageal varices, gastric ulcers, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric mucosal polyps, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, elevated creatine kinase, increased serum and urine myoglobin, cutaneous lupus erythematosus, arthralgia, cytopenia, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis
Not everyone experiences these, and they can vary from person to person.
Storage
This drug may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Also, it is best to store it at room temperature, avoiding direct sunlight.
Appearance and packaging
Appearance
An opaque purple hard capsule containing white to pale yellowish granules.
Package unit
28 capsules (7 capsules/Alu-Alu x 4)
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
